

A faculty of leading international haematologists will explore the evolving treatment landscape in follicular lymphoma (FL) and chronic lymphocytic leukaemia (CLL), focussing on the role of targeted therapies, selecting the appropriate therapy and the practical considerations of managing patients. We look forward to welcoming you to what promises to be a highly informative and engaging meeting.

Meeting Co-chairs:

- Ulrich Jäger,
Vienna, Austria
- Paolo Ghia,
Milan, Italy

To register please contact:

Roger Hax
email: roger.hax@gilead.com

EXPERT FORUM INVITATION

Rethinking approaches to B-cell malignancies

JOIN US AT
THE HILTON LONDON METROPOLE
LONDON, UK
9-10 MARCH 2018



This meeting is organised and funded by Gilead Sciences Europe Ltd.

Gilead Sciences Netherlands B.V., Claude Debussylaan 22, 1082 MD Amsterdam
www.gilead.com

ZDG/NL/17-11//1787
Date of preparation: November 2017



Expert Forum: Friday 9 March Day 1 agenda

13:30-17:30

Topic

Chair's welcome Day 1

Targeting the tumour microenvironment via the PI3K pathway

Choosing the right therapy: How I manage my FL patients

Managing high-risk FL in the era of targeted therapy

Spotlight on clinical practice: High-risk FL, Q&A 🔍

Coffee break

Is transplantation still relevant in the era of targeted therapies?

Spotlight on clinical practice: Peri-transplant setting, Q&A 🔍

Treatment decisions: How have they changed since the introduction of targeted agents?

From Phase III trials to real world experience: What have we learned about PI3K inhibition in B-cell malignancies?

Panel discussion

Day 1 close

Speaker

Ulrich Jäger

Klaus Okkenhaug

Michele Ghilmini

Pier Luigi Zinzani

Raúl Córdoba

Johannes Schetelig

Pier Luigi Zinzani

Clemens-Martin Wendtner

Ulrich Jäger

All Faculty

Ulrich Jäger

Expert Forum: Saturday 10 March Day 2 agenda

08:30-12:30

Topic

Chair's welcome Day 2

Prognostication in the era of targeted therapies: What has changed?

Targeted therapies in prognostic subgroups: The evidence to date

What are the drivers of early relapse in CLL?

Spotlight on clinical practice: Early relapse CLL, Q&A 🔍

Coffee break

Choosing the right therapy: How I manage my CLL patients

Spotlight on clinical practice: High-risk CLL, Q&A 🔍

Panel discussion

Meeting summary and close

Speaker

Paolo Ghia

Florence Cymbalista

Clemens-Martin Wendtner

Anna Schuh

Javier Loscertales Pueyo

Paolo Ghia

*Robert Ayto
Erica Finolezzi*

All Faculty

Paolo Ghia